<?xml version="1.0" encoding="UTF-8"?>
<fig id="Fig6">
 <label>Fig. 6</label>
 <caption>
  <p>EQ-5D overall index score change from pre-ASCT baseline values (adjusted). EQ-5D score scale is − 0.109 to 1. 
   <bold>a</bold> Any maintenance therapy versus no maintenance therapy. 
   <bold>b</bold> Lenalidomide-only maintenance therapy versus no maintenance therapy. 
   <bold>c</bold> HRQoL at baseline, pre-ASCT, during follow-up, and at PD. 
   <italic>P</italic> values are paired 
   <italic>t</italic> test comparisons between periods within treatment group. Autologous stem cell transplant (ASCT), EuroQol Research Foundation questionnaire (EQ-5D), lenalidomide (LEN), least-squares (LS), progressive disease (PD). 
   <sup>a</sup>LS mean during the analysis period, 
   <sup>b</sup>44 patients in the LEN-only maintenance group had PD
  </p>
 </caption>
 <graphic xlink:href="277_2018_3446_Fig6_HTML" id="MO6" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
